Last week in GLP1 (2025/10/06)

GLP1.Guide Staff

06 Oct 2025 — 1 min read

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed:

💼 Costco is now selling heavily discounted GLP1s

🦘 Buzz in Australia around GLP1s as a public benefit

💊 Excitement is growing around oral GLP1s

🏫 Harvard doctor doubles down on benefits of GLP1 for inflammation

🏆 Svetlana Mojsov, GLP1 creator, wins 2026 Kimberly Prize

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:

Read the rest on Substack

Oral GLP1s you've probably never heard of

Most people have heard of Mounjaro, Zepbound, Wegovy, Ozempic and Rybelsus by now. The words “VK2735” or “Orforglipron” mean nothing to most people, though now almost everyone is familiar with GLP1s as a class of drugs (at the very least the effects). There are some obscure GLP1s under development that

Last week in GLP1 (2025/10/13)

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 🔎 GLP1 interfering with medical imaging? 💚 More research on GLP1’s benefits for stopping substance & alcohol Abuse 📑 Ketones + GLP1s prevent muscle loss (in mice) 🚨 Semaglutide Withdrawal and it’s effects on Type

Last week in GLP1 (2025/09/22)

Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective

A new study on GLP1s eye risk

One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration. We’ve covered this before: The link between Semaglutide & vision loss (NAION)How deep is the link between GLP1s and possible vision loss? We examine